Compile Data Set for Download or QSAR
Report error Found 37 Enz. Inhib. hit(s) with all data for entry = 11351
TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM575622(US11459340, Compound 1 | (6-((2-amino-3-chloropyri...)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609055(US11702411, Compound 30)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609054(US11702411, Compound 29)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609053(US11702411, Compound 28)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609057(US11702411, Compound 32)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608866([6-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-3-[(3S,4...)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608821((6-((2-amino-3-chloropyridin-4-yl)thio)-3-(4-amino...)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608966(US11702411, Compound 11)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609040(US11702411, Compound 15)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609044(US11702411, Compound 19)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609048(US11702411, Compound 23)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609047(3-({5-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4...)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609046(US11702411, Compound 21)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609052(US11702411, Compound 27)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609051({3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]...)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609050(US11702411, Compound 25)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609049(US11702411, Compound 24)
Affinity DataIC50: 50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608819(US11702411, Example 2 | US11702411, Compound 2)
Affinity DataIC50: 88nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608817(US11702411, Example 1 | US11702411, Compound 1)
Affinity DataIC50: 145nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608820(US11702411, Example 3 | US11702411, Compound 3)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608819(US11702411, Example 2 | US11702411, Compound 2)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609059(US11702411, Compound 35)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608817(US11702411, Example 1 | US11702411, Compound 1)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609058(US11702411, Compound 34)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608867({3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]...)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608960({3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]...)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608959(US11702411, Compound 9)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608924(2-{5-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4....)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608993(US11702411, Compound 14)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608992(US11702411, Compound 13)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609043(US11702411, Compound 18)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609041(US11702411, Compound 16)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609045(US11702411, Compound 20)
Affinity DataIC50: 275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608820(US11702411, Example 3 | US11702411, Compound 3)
Affinity DataIC50: 461nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608967(US11702411, Compound 12)
Affinity DataIC50: 500nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM609042(US11702411, Compound 17)
Affinity DataIC50: 500nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Revolution Medicines

US Patent
LigandPNGBDBM608923({3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]...)
Affinity DataIC50: 500nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent